CLSA: Cuts Alibaba Health (00241.HK) target price to HK$3.7; nutritional supplement regulatory headwinds weigh on revenue outlook

Zhito Finance APP has learned that CLSA issued a research report stating that Alibaba Health (00241.HK) lowered its FY2027 revenue outlook, mainly due to subsidy cuts and regulatory headwinds that weakened nutritional supplement sales, while pharmaceutical sales remained solid, achieving high-teens year-on-year growth. The bank lowered its FY2027 to FY2028 adjusted net profit forecasts by 6% to 7%, and cut its target price from HK$4.7 to HK$3.7, maintaining an "Outperform" rating.